Literature DB >> 10322872

[Clinical study of bugu shengsui capsule in treating primary osteoporosis with kidney-yang deficiency syndrome].

Y M Xie1, F Z Zhang, W Q Zhou.   

Abstract

OBJECTIVE: To assess the effect of Bugu Shengsui capsule (BGSSC) in treating primary osteoporosis.
METHODS: Using double energy X-ray bone densimeter and radioimmunoassay (RIA), the effect of BGSSC in treating primary osteoporosis (OP) with Kidney-Yang Deficiency syndrome.
RESULTS: The clinical markedly effective and total effective rates of BGSSC were 46% and 82%, respectively. The rate of TCM group is significantly higher than that of the control group (Vitamin D plus calcium). BGSSC could improve bone mineral density by the verification of double energy X-ray bone dansity (DEXA). It could also increase the level of serum calcitonin, luteinizing hormone and calcium, decrease the activity of parathyroid hormone.
CONCLUSIONS: The effects of BGSSC on primary OP included increasing patient's bone mineral density, depressing bone resorption and decreasing bone loss.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10322872

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

1.  Quantitative Proteomics Revealed the Pharmacodynamic Network of Bugu Shengsui Decoction Promoting Osteoblast Proliferation.

Authors:  Xu Wei; Baoyu Qi; Ruyun Ma; Yili Zhang; Ning Liu; Shengjie Fang; Yanning Zhu; Yanming Xie; Jianye Dai; Liguo Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-25       Impact factor: 5.555

2.  Bu-Gu-Sheng-Sui decoction promotes osteogenesis via activating the ERK/Smad signaling pathways.

Authors:  Ning Liu; Baoyu Qi; Yili Zhang; Shengjie Fang; Chuanrui Sun; Qiuyue Li; Xu Wei
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.